Advertisement


Muhit Özcan, MD, on CLL/SLL: Report on a Still-Recruiting International Study of Nemtabrutinib, Venetoclax, and Rituximab

2024 ASCO Annual Meeting

Advertisement

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses the ongoing phase III BELLWAVE-010 study of nemtabrutinib plus venetoclax vs venetoclax plus rituximab in previously treated patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (Abstract TPS7089).  



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
[Inaudible 00:00:08] is a standard of care option for patients with CLL, SLL, who have relapsed after at least one line of prior therapy. However, there is an unmet need for more effective treatments. Bruton tyrosine kinase, BTK, plays an important role in the pathogenesis of CLL. Nemtabrutinib is a BTK inhibitor that targets both wild-type and C-481 mutant forms of BTK, in the ongoing BELLWAVE-001 study, nemtabrutinib demonstrates manageable safety and durable anti-tumor activity in patients with refractory relapse, CLL, SLL, with and without C-481 mutations. The randomized open-label phase III BELLWAVE zero-tense study is designed to evaluate the efficacy and safety of nemtabrutinib plus venetoclax versus VR as a second line or later treatment for patients with RR CLL, SLL. Eligible patients are aged more than 18 years with active refractory relapse CLL, SLL after at least one line on prior therapy per IW-CLL 2018 criteria, and equal performance status of zero to two approximately 720 patients will be enrolled in two parts. Part one is an open-label, non-randomized dose escalation and confirmation phase to evaluate safety, and determine the optimal dose of nemtabrutinib plus venetoclax. Part one will enroll 30 patients to establish the dose of nemtabrutinib, using a modified toxicity probability interval design. Patients will receive nemtabrutinib at two dose levels. 45 milligram per day parallel Q-day, starting dose. Escalating to six five milligram parallel Q-day for 28 days, followed by nemtabrutinib plus venetoclax ramp up over four weeks. Part two is an open-label parallel group randomized phase comparing the efficacy and safety of nemtabrutinib plus venetoclax with VR. In part two, approximately 690 patients will be randomly assigned one-to-one to receive either nemtabrutinib at recommended dose for 28 days, followed by the nemtabrutinib plus venetoclax, or venetoclax plus rituximab. Study treatment will continue for approximately two years, or until an acceptable toxicity, disease progression, or other discontinuation criteria are met. Randomization will be certified by BTKC-481 mutation status, geographic region, and risk group. The primary endpoint for part two is progression free survival by Blinded Independent Central Review, BICR, per IWCLL 2018 criteria. Secondary endpoints for part two are: Undetectable, minimal residual disease in bone marrow at month 14 by central laboratory assessment, objective response rate and duration of response by BICR per IWCLL 2018 criteria, Overall survival and safety. Exploratory endpoints are overall response rate, including partial response with lymphocytosis, pharmacokinetics, and heart-related quality of life. Recruitment is ongoing.

Related Videos

Lung Cancer

Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent

Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of patients with advanced non–small cell lung cancer (Abstract 8601).

Pancreatic Cancer

Belinda Lee, MBBS, on Early-Stage Pancreatic Cancer: New Data on Guiding Adjuvant Chemotherapy

Belinda Lee, MBBS, of Peter MacCallum Cancer Centre, Northern Health, Walter & Eliza Hall Institute, Melbourne, discusses findings from the AGITG DYNAMIC-Pancreas trial on the potential role of serial circulating tumor DNA testing after upfront surgery to guide adjuvant chemotherapy for early-stage disease (Abstract 107).

Breast Cancer

Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy

Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Tarah J. Ballinger, MD, of Indiana University Simon Comprehensive Cancer Center, discuss the disparate burden of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer and how a tailored trial for this population showed that using docetaxel as the preferred taxane may be beneficial (LBA503).

Bladder Cancer

Jonathan E. Rosenberg, MD, and Thomas Powles, MD, PhD, on Urothelial Carcinoma: Expert Commentary on Two Key Abstracts

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, discuss phase III findings from two studies: the first, investigating enfortumab vedotin-ejfv and pembrolizumab vs platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer; and the second, looking at nivolumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone in patients with lymph node–only metastatic disease enrolled in the CheckMate 901 trial (Abstracts 4581 and 4565).

Breast Cancer

Sherene Loi, MD, PhD, on Early-Stage Breast Cancer: Weighing the Prognostic Value of ctDNA Detection

Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre, discusses a circulating tumor DNA (ctDNA) analysis from a cohort of patients with early-stage breast cancer who were enrolled in the monarchE trial. This large cohort was studied to look at the usefulness of a personalized tumor-informed assay for ctDNA detection in early stage high-risk patients (LBA507).

Advertisement

Advertisement




Advertisement